On Friday, Immunome Inc (NASDAQ: IMNM) was -3.98% drop from the session before settling in for the closing price of $7.28. A 52-week range for IMNM has been $6.94 – $25.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -7.10% over the last five years. When this article was written, the company’s average yearly earnings per share was at 46.10%. With a float of $75.59 million, this company’s outstanding shares have now reached $86.95 million.
The firm has a total of 118 workers. Let’s measure their productivity. In terms of profitability, gross margin is 89.65%, operating margin of -3382.37%, and the pretax margin is -3240.38%.
Immunome Inc (IMNM) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Immunome Inc stocks. The insider ownership of Immunome Inc is 13.07%, while institutional ownership is 61.43%. The most recent insider transaction that took place on Mar 25 ’25, was worth 60,684. In this transaction Director of this company bought 7,800 shares at a rate of $7.78, taking the stock ownership to the 31,415 shares. Before that another transaction happened on Mar 26 ’25, when Company’s President and CEO bought 137,100 for $7.29, making the entire transaction worth $999,459. This insider now owns 806,736 shares in total.
Immunome Inc (IMNM) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 46.10% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.77% during the next five years compared to -38.15% drop over the previous five years of trading.
Immunome Inc (NASDAQ: IMNM) Trading Performance Indicators
You can see what Immunome Inc (IMNM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.08. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 67.23.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.18, a number that is poised to hit -0.67 in the next quarter and is forecasted to reach -2.87 in one year’s time.
Technical Analysis of Immunome Inc (IMNM)
Analysing the last 5-days average volume posted by the [Immunome Inc, IMNM], we can find that recorded value of 1.4 million was better than the volume posted last year of 0.98 million. As of the previous 9 days, the stock’s Stochastic %D was 8.69%. Additionally, its Average True Range was 0.64.
During the past 100 days, Immunome Inc’s (IMNM) raw stochastic average was set at 1.09%, which indicates a significant decrease from 3.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 83.64% in the past 14 days, which was higher than the 79.81% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.49, while its 200-day Moving Average is $12.13. Now, the first resistance to watch is $7.23. This is followed by the second major resistance level at $7.48. The third major resistance level sits at $7.64. If the price goes on to break the first support level at $6.82, it is likely to go to the next support level at $6.66. Should the price break the second support level, the third support level stands at $6.41.
Immunome Inc (NASDAQ: IMNM) Key Stats
There are 86,951K outstanding shares of the company, which has a market capitalization of 607.79 million. As of now, sales total 9,040 K while income totals -292,960 K. Its latest quarter income was 2,740 K while its last quarter net income were -80,250 K.
